80% of sales are won or lost in 3 seconds - Future of Marketing Keynote Speaker - Pardavimu formule

Trust is the Most Important Thing You Sell. Reputational risk - leadership, health, retail keynote

Funny stories about simple mistakes many companies make. Small things make MAGIC and often cost NOTHING to deliver well. Marketing Keynote for Confinn

Life's too short to do things you don't believe in! Why passionate belief in the true value of what you are selling or doing is the number one key to success. Secret of all leadership and marketing - keynote for 1100 people in Vilnius October 2021

Why you HAVE to MEET to close deals. Want to make change happen and innovate? Get your teams into the office. Sales beyond COVID. Marketing keynote speaker - 1100 people

Join me: Accenture SustainABILITY event, Lisbon, Portugal. Keynote on Sustainability and Technology

Future of Sales and Marketing beyond COVID - audience of 800 in Vilnius. Digital marketing, location marketing. How to create MAGIC in new marketing campaigns. Future of Marketing Keynote Speaker

Why this is boom-time for physical corporate events in some nations following COVID vaccinations - future of conferencing, keynote speakers. Get ready for hyper-agile pop-up events at short notice. Companies have to meet to survive. CALL NOW +447768511390

Huge Tomatoes from Exhaust Gas in Power Generation, and re-use of heat. Greentech Innovation, CO2 emissions reduction, energy and food industry - climate emergency keynote speaker - VIDEO

For YEARS I warned about new pandemic risks. Life beyond COVID - impact on health care innovation, vaccines, future of pharma research and drug development. Future of Health care Keynote Speaker and Physician who warned for years about new pandemic risks

Life Beyond COVID. Virtual Event Futurist Keynote Speaker.High audience engagement on COVID. Patrick Dixon is one of the world's leading keynote speakers on health care

Q+A on COVID: global impact - with Futurist physician advisor to corporations and government. COVID keynote speaker - health care trends

Micro-dose chemo for cancer using oncolytic viruses. Cancer therapy - future healthcare

Futurist Keynote Speaker: Posts, Slides, Videos - BioTech and MedTech Keynote Speaker

More: http://www.virttu.com. How oncolytic viruses can target radiotherapy - micro-dose radiation to kill cancer cells. Replication of oncolytic viruses inside tumours. Pre-clinical trials. Phase I, Phase II and Phase III clinical trials on oncolytics. Use of oncolytic viruses to treat advanced malignant melanoma and mestatases -- Amgen research using an oncolytic virus developed from HSV (Herpes Simplex Virus). Oncolytic virus conference 2013. Problems with traditional chemotherapy -- side effects. Why Amgen bought an oncolytic viruse for $500m in cash and $500m to be paid if oncolytic trials are fully successful. Investor interest in oncolytic viruses. Oncolytic virus fund. Lessons from the history of research and development in monoclonal antibodies in cancer treatment. Why targeted cancer therapy -- a so-called "magic bullet" is so needed. How oncolytic viruses have been modified so that they cannot replicate in normal cells, but are still able to divide in a wide variety of human cancer cells. History of oncolytic viruses. Arming oncolytic viruses. Using viruses like Seprehvir (HSV-1716), adapted to carry an additional payload: extra genes which teach infected cancer cells to take up a compound containing radioactive iodine from the blood, delivering a micro-dose of radiation inside individual cancer calls. Or adding a gene which teaches cancer cells how to split a harmless pro-drug into two, inside the cell, releasing a very effective chemotherapy (alkylating agent). Targetting oncolytic viruses -- by adapting the feet of a virus to that they latch onto receptors on the surface of specific human cancer cells such as prostate (prostate antigens / PSA). Oncolytic virotherapy: Results of early Phase III Rheolysin clinical trials -- combined oncolytic virus and cancer chemotherapy. Side effects and safety profile of oncolytic viruses in clinical studies. Oncolytic virus Seprehvir has passed an FDA safety review with approval for systemic administration of oncolytic viruses to children with advanced cancer. How genes work in viruses, and how genetic engineering allows us to cut and paste genes from one species into another. Dr Video made by Patrick Dixon author of The Genetic Revolution, Chairman of Global Change Ltd, an advisor to many large pharma companies and Chairman of Virttu Biologics Ltd which owns the oncolytic virus Seprehvir (HSV-1716) and many other variants. Seprehvir has been shown to be highly effective against a wide range of cancers in pre-clinical studies. Seprehvir has been used in clinical trials with strong evidence of impact and almost negligible side effects - trials in glioblastoma (brain cancer), squamous cell carcinoma of head and neck and melanoma. Seprehvir is now being used in clinical trials for mesothelioma (lung cancer caused by asbestos), with others planned for hepatocellular carcinoma (live cancer) and ovarian cancer. OncoVEX GM-CSF developed by BioVex in phase III for advanced melanoma, could become first approved oncolytic virus in the western world. OncoVEX GM-CSF is also in a phase 3 trial for head and neck cancer. Reolysin (owned by Oncolytics Biotech) is in phase 3 clinical trials for head and neck cancer with early results in colorectal cancer. JX-594 is owned by Jennerex and in clinical trials for hepatocellular carcinoma. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF. NTX-010 is in clinical trials for small cell lung cancer and neuroblastoma. CGTG-102 (Ad5/3-D24-GMCSF) is owned by Oncos Therapeutics. GL-ONC1 is owned by Genelux in Phase I clinicla trials. Cavatak is being developed to treat malignant melanoma. Oncorine was approved a few years ago in China for treatment of head and neck cancer - built from H101 virus.

Declaration of interest: after writing this article, the author became Chairman of Virttu Biologics Ltd.  The company was subsequently bought by Sorrento Therapeutics Inc in 2017.

http://www.youtube.com/watch?v=Y3VneIw5dBo


Related news items:
Newer news items:
Older news items:


Thanks for promoting with Facebook LIKE or Tweet. Really interested to read your views. Post below.

Join the Debate! What are your own views?


?

 

Search for your future



Our cookie policy

We use cookies for statistical purposes. To comply with the e-Privacy Directive we need to ask your consent to place these cookies on your computer.

Your use of this site indicates acceptance of these terms. I accept